Skip header and navigation

3 records – page 1 of 1.

[Electroconvulsive therapy in treatment of depression]

https://arctichealth.org/en/permalink/ahliterature77790
Source
Ugeskr Laeger. 2007 Apr 16;169(16):1447-50
Publication Type
Article
Date
Apr-16-2007
Author
Bolwig Tom G
Author Affiliation
Rigshospitalet, Psykiatrisk Klinik, København Ø. tom.g.bolwig@rh.hosp.dk
Source
Ugeskr Laeger. 2007 Apr 16;169(16):1447-50
Date
Apr-16-2007
Language
Danish
Publication Type
Article
Keywords
Depressive Disorder - therapy
Electroconvulsive Therapy - adverse effects - methods
Humans
Treatment Outcome
Abstract
ECT is the most powerful treatment of severe melancholic/ psychotic depression. A treatment series consists of 8-12 sessions, given 3 times a week under anaesthesia, muscle relaxation and artificial ventilation with 100% oxygen. EEG, EMG, EKG and pulse oximetry are monitored. Benzodiazepines, anticonvulsants and lithium salts should be avoided during treatment with ECT. Ambulatory single ECT sessions with an interval of 3-4 weeks (maintenance-ECT) is recommended in drug-resistant depression. In Denmark, 5% of all patients admitted to psychiatric departments were treated with ECT; 18% of patients diagnosed with depression were given ECT. ECT is a safe and sometimes life-saving treatment.
PubMed ID
17484843 View in PubMed
Less detail

[New insights into electroconvulsive therapy].

https://arctichealth.org/en/permalink/ahliterature179337
Source
Duodecim. 2004;120(10):1219-25
Publication Type
Article
Date
2004
Author
Pertti Heikman
Author Affiliation
Helsingin yliopisto Kliininen laitos, HYKS:n psykiatrian klinikka, Lapinlahden sairaala PL 320, 00029 HUS. pertti.heikman@hel.fi
Source
Duodecim. 2004;120(10):1219-25
Date
2004
Language
Finnish
Publication Type
Article
Keywords
Depressive Disorder - diagnosis - therapy
Electroconvulsive Therapy - adverse effects - methods
Female
Finland
Humans
Male
Prognosis
Risk assessment
Seizures - epidemiology - etiology
Severity of Illness Index
Treatment Outcome
PubMed ID
15232980 View in PubMed
Less detail

The study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disorder.

https://arctichealth.org/en/permalink/ahliterature97936
Source
BMC Psychiatry. 2010;10:16
Publication Type
Article
Date
2010
Author
Ute Kessler
Arne E Vaaler
Helle Schøyen
Ketil J Oedegaard
Per Bergsholm
Ole A Andreassen
Ulrik F Malt
Gunnar Morken
Author Affiliation
Moodnet Research Group, Haukeland University Hospital, Bergen, Norway. ute.kessler@helse-bergen.no
Source
BMC Psychiatry. 2010;10:16
Date
2010
Language
English
Publication Type
Article
Keywords
Adult
Bipolar Disorder - drug therapy - epidemiology - therapy
Clinical Protocols
Cognition Disorders - diagnosis - etiology
Drug resistance
Drug Toxicity - diagnosis
Electroconvulsive Therapy - adverse effects - methods
Female
Humans
Male
Neuropsychological Tests
Norway - epidemiology
Overdose - epidemiology
Pregnancy
Pregnancy outcome
Prospective Studies
Psychiatric Status Rating Scales
Psychotropic Drugs - therapeutic use
Quality of Life
Questionnaires
Suicide - psychology - statistics & numerical data
Suicide, Attempted - statistics & numerical data
Treatment Outcome
Abstract
BACKGROUND: The treatment of depressive phases of bipolar disorder is challenging. The effects of the commonly used antidepressants in bipolar depression are questionable. Electroconvulsive therapy is generally considered to be the most effective treatment even if there are no randomized controlled trials of electroconvulsive therapy in bipolar depression. The safety of electroconvulsive therapy is well documented, but there are some controversies as to the cognitive side effects. The aim of this study is to compare the effects and side effects of electroconvulsive therapy to pharmacological treatment in treatment resistant bipolar depression. Cognitive changes and quality of life during the treatment will be assessed. METHODS/DESIGN: A prospective, randomised controlled, multi-centre six- week acute treatment trial with seven clinical assessments. Follow up visit at 26 weeks or until remission (max 52 weeks). A neuropsychological test battery designed to be sensitive to changes in cognitive function will be used. Setting: Nine study centres across Norway, all acute psychiatric departments. Sample: n = 132 patients, aged 18 and over, who fulfil criteria for treatment resistant depression in bipolar disorder, Montgomery Asberg Depression Rating Scale Score of at least 25 at baseline. Intervention: Intervention group: 3 sessions per week for up to 6 weeks, total up to 18 sessions. Control group: algorithm-based pharmacological treatment as usual. DISCUSSION: This study is the first randomized controlled trial that aims to investigate whether electroconvulsive therapy is better than pharmacological treatment as usual in treatment resistant bipolar depression. Possible long lasting cognitive side effects will be evaluated. The study is investigator initiated, without support from industry. TRIAL REGISTRATION: NCT00664976.
PubMed ID
20178636 View in PubMed
Less detail